319例注射用脑蛋白水解物药品不良反应报告分析

doi:10.19803/j.1672-8629.20230653

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (2): 195-198.
DOI: 10.19803/j.1672-8629.20230653

319例注射用脑蛋白水解物药品不良反应报告分析

李应芬, 韩雷^*

曲靖市食品药品不良反应与药物滥用监测中心,云南曲靖 655000

收稿日期:2023-10-18 出版日期:2024-02-15 发布日期:2024-02-06
通讯作者: ^*韩雷,男,本科,药品不良反应监测与评价。E-mail: 806899694@qq.com
作者简介:李应芬,女,本科,副主任药师,药品不良反应监测与评价。

Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection

LI Yingfen, HAN Lei^*

Qujing Food and Drug Adverse Reaction and Drug Abuse Monitoring Center, Qujing Yunnan 655000, China

Received:2023-10-18 Online:2024-02-15 Published:2024-02-06

摘要/Abstract

摘要： 目的分析注射用脑蛋白水解物不良反应报告数据,了解该药品不良反应发生特点,为临床安全用药提供参考。方法采用回顾性研究,对2011年1月1日至2022年12月31日收集到的注射用脑蛋白水解物不良反应报告进行分析。结果 319例注射用脑蛋白水解物不良反应累计598例次,多发生于61岁以上患者,不良反应发生时间多为用药30 min内,不良反应累及系统-器官主要为皮肤及其附件疾病、胃肠疾病、呼吸系统疾病等。严重报告56例,不良反应主要表现为过敏样反应。结论临床应警惕注射用脑蛋白水解物引起的不良反应,规范临床用药,防止过敏性休克严重不良反应的发生。

关键词: 注射用, 脑蛋白水解物, 药品不良反应, 合理用药, 过敏性休克, 过敏样反应

Abstract: Objective To analyze the adverse drug reactions (ADR) induced by cerebroprotein hydrolysate for injection and to find out about the characteristics of such ADR so as to provide data for safe clinical use of cerebroprotein hydrolysate for injection. Methods Data on ADR of cerebroprotein hydrolysate for injection between 2011 and 2022 was collected by Qujing Food and Drug Adverse Reaction and Drug Abuse Monitoring Center. Results Most of the 319 cases of adverse reaction caused by cerebroprotein hydrolysate for injection occurred in patients over 61 years old. Adverse reaction usually occurred within 30 minutes of medication and manifested themselves in skin and appendages disorders, gastrointestinal disorders, and respiratory disorders. There were a total of 56 cases of severe ADR that were characterized by anaphylactoid reaction and anaphylactic shock. Conclusion Clinicians should be alert to ADR caused by cerebroprotein hydrolysate for injection in clinical practice, standardize clinical medication, prevent the occurrence of such serious adverse reactions as anaphylaxis.

Key words: injection, cerebroprotein hydrolysate, adverse drug reaction, rational drug use, anaphylaxis shock, anaphylactoid reaction

中图分类号:

R971
R994.11

李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.

LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.zgywjj.com/CN/10.19803/j.1672-8629.20230653

https://www.zgywjj.com/CN/Y2024/V21/I2/195

参考文献

[1] ZHANG TT, HU YZ.Advances in the research of cerebroprotein hydrolysate medicine with the cranial nerve diseases[J]. World Clinical Drugs(世界临床药物), 2020, 41(9): 747-751.
[2] LAI BY.Effect of cerebroprotein hydrolysate on ischemic cerebrovascular disease[J]. Heilongjiang Journal of Traditional Chinese Medicine(黑龙江中医药), 2020, 49(4): 115-116.
[3] DENG GJ.Clinical effects of cerebroprotein hydrolysate oral liquid on patients with cognitive impairment after stroke[J]. China Journal of Pharmaceutical Economics(中国药物经济学), 2019, 14(12): 63-65.
[4] LIN H, ZHOU E, HUANG BF.Clinical effect of cerebroprotein hydrolysate on patients with hypertensive intracerebral hemorrhage after evacuation of intracranial hematoma[J]. Chinese Journal of Clinical Rational Drug Use(临床合理用药), 2023, 16(10): 67-70.
[5] WANG YM, JIN YH, JIANG H.Experience in rescue and nursing care of a patient with anaphylaxis caused by cerebroprotein hydrolysate injection[J].Guide of China Medicine(中国医药指南), 2014, 12(10): 213.
[6] LIU L, SHI RY.A case of anaphylaxis caused by cerebroprotein hydrolysate for injection[J]. Gansu Medical Journal(甘肃医药), 2018, 37(2): 192.
[7] ZHANG HM, HOU JQ, ZHOU W.Two cases of anaphylaxis caused by troxerutin and cerebroprotein hydrolysate injection[J]. Herald of Medicine(医药导报), 2020, 39(2): 245-246.
[8] WANG D.A case of anaphylaxis caused by cerebroprotein hydrolysate for injection[J]. China’s Naturopathy(中国民间疗法), 2014, 22(6): 68.
[9] YPK. Package Insert of Cerebroprotein Hydrolysate Injection[EB/OL].[2023-12-07]. https://ypk.39.net/590219/manual/.
[10] EMILY M, KYAN M, THELEN VB, et al.Perinatal androgens organize sex differences in mast cells and attenuate anaphylaxis severity into adulthood[J]. Proceedings of the National Academy of Sciences, 2020, 117(38): 23751-23761.
[11] LI XL, WANG YL, ZHANG AP.Cause analysis and countermeasures of adverse drug reactions of traditional Chinese medicine injection[J]. Proceeding of Clinical Medicine(临床医药实践), 2020, 29(5): 388-390.
[12] TIAN J.Research progress on clinical application of brain protein hydrolysate[J]. Medical Innovation of China(中国医药创新), 2010, 7(2): 121-122.
[13] YE LC,MAO SZ.Research progress on pharmacological action and clinical application of brain protein hydrolysate[J]. Herald of Medicine(医药导报), 2008, 27(1): 72-73.
[14] CHEN L.Effect of cerebroprotein hydrolysate on neonatal hypoxic-ischemic encephalopathy[J]. Chinese Health Care(中华养生保健), 2021, 39(2): 36-37.
[15] ZHAO Q, XU YR, WANG XB.Analysis of clinical drug use of troxerutin and cerebroprotein hydrolysate injection[J]. Journal of China Prescription Drug(中国处方药), 2020, 18(8): 53-55.
[16] National Medical Products Administration. Notice in National Medical Products Administration on the revision of the instructions for cerebroprotein hydrolysate injections[EB/OL].(2016-11-10)[2023-06-13]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/ypshmshxdgg/20161110203201653.html.
[17] YANG YB, ZHANG ZY, WEI CH.Quality standard and adverse reactions of cerebroprotein hydrolysate preparations[J]. China Pharmacy(中国药房), 2012, 23(1): 82-84.
[18] National Health Commission of the People’s Republic of China. Circular of the General Office of the National Health Commission on the issuance of the second national catalogue of drugs for rational use[EB/OL]. (2023-01-15)[2023-12-07]. http://www.nhc.gov.cn/yzygj/s7659/202301/5b291aaae64b4e56a10f9ea910e11426.shtml.

319例注射用脑蛋白水解物药品不良反应报告分析

Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	余馨, 贡磊磊, 姚伟洁, 袁偲偲, 冯欣. 中成药治疗复发性流产的临床研究概况性综述[J]. 中国药物警戒, 2024, 21(4): 361-365.
[2]	杨波, 王梦娇, 胡丽丽, 王来成, 李倩, 孔飞飞, 吕冬梅, 沈佳妮. 385例PD-1抗肿瘤治疗的安全性研究及风险因素分析[J]. 中国药物警戒, 2024, 21(4): 447-450.
[3]	黎海燕, 杨忠旭, 刘跃昆, 王丽虹. 1例甲氨蝶呤治疗异位妊娠致严重不良反应患者的药学监护[J]. 中国药物警戒, 2024, 21(4): 454-456.
[4]	孙武, 陈水龄, 周婉瑜, 史航, 刘璐, 贺严, 付文涛, 褚利群. TNF-α抑制剂注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白/注射用依那西普致葡萄膜炎2例分析[J]. 中国药物警戒, 2024, 21(4): 457-460.
[5]	李少强, 孔旭东, 李朋梅. 注射用奥美拉唑钠致低钠血症1例分析[J]. 中国药物警戒, 2024, 21(4): 461-463.
[6]	伍诗琪, 闫素英, 张青霞. 艾多沙班药代动力学相互作用研究进展[J]. 中国药物警戒, 2024, 21(4): 473-480.
[7]	黄焕均, 麦嘉恒, 张云惠, 郭晨晨, 梁蔚婷. 613例抗肿瘤药物的不良反应分析[J]. 中国药物警戒, 2024, 21(3): 324-328.
[8]	吉秋霞, 金剑, 章斌. 特瑞普利单抗免疫相关不良事件药学监护[J]. 中国药物警戒, 2024, 21(3): 346-348.
[9]	陈杰, 张斌, 赵俊, 张传洲. 托珠单抗注射液致过敏性休克1例分析[J]. 中国药物警戒, 2024, 21(3): 349-351.
[10]	杨雪婷, 何波, 闫鸿丽, 李冬梅. 克拉霉素致急性短暂性抑郁症不良反应1例分析[J]. 中国药物警戒, 2024, 21(3): 352-354.
[11]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[12]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[13]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[14]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[15]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.